Analyst Consensus ?
ConsensusBuy4 ratings
Bullish4100.0%
Neutral00.0%
Bearish00.0%
Jbs N.V. · JBS · FY2026 Q3 · Calendar Q4 2026
JBS Sees U.S. Beef Turn Positive, While Pork and Cash Flow Weigh
The quarter presents a mixed operating picture: improvement in U.S. beef and diversification through Flora support the business outlook, while pork weakness, inventory-related cash use and leverage temper the case for sustained improvement.
Why did JBS fall 5.5% after missing EPS estimates in FY2026 Q3?
Research this report with FN2. Free to start; review your question before sending.
Reported After market closeNYSEConsumer Defensive
$29.10B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.16
Consensus $0.22
EPS surprise
-28.6%
Reported versus consensus
Reported revenue
$22.74B
Consensus $22.78B
Revenue surprise
-0.2%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-5.5%
Event window
SPY move
-0.4%
Same window
Abnormal move
-5.1%
Stock minus SPY
Volume
2.4×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
JBSSPY benchmark
Ask FN2 about JBS FY2026 Q3
Choose a question to continue your research
Why did JBS fall 5.5% after missing EPS estimates in FY2026 Q3?What changed in JBS's guidance and outlook in FY2026 Q3?Give me the bull and bear case for JBS after FY2026 Q3 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
The supplied Q3 analysis highlights U.S. beef returning to positive adjusted EBITDA and the Flora acquisition adding consumer-goods and nutrition exposure. Pork profitability remains pressured, and management plans lower 2027 capital spending with more emphasis on maintenance. This contrasts with the prior quarter's stronger pork margins and positive free cash flow.
Guidance delta
Formal guidance was not provided in the supplied analysis. Management commentary points to sequential U.S. beef margin recovery into Q4 and 2027, while pork pressure may persist into early 2027; the analysis also describes expectations for a better Q4.
Key takeaways
- U.S. beef profitability improved, but the durability and scale of margin recovery remain open questions.
- Pork oversupply and weaker demand continue to pressure profitability and may persist into early 2027.
- Flora broadens the portfolio, while planned capex reductions may support cash discipline but could constrain growth investment.
Management priorities
- Integrate Flora and develop the Genu-in nutrition platform and B2C channels.
- Improve operating performance in U.S. beef and pork, while building export opportunities in Europe and China.
- Reduce 2027 capex with greater focus on maintenance and continue addressing leverage.
Follow JBS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$12.15Current
$17Low
$18.33Average
$20High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 11, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| JP Morgan | Overweight | Overweight | Maintain | Oct 22, 2026 |
| UBS | Buy | Buy | Maintain | Aug 24, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Aug 17, 2026 |
| Barclays | Overweight | Overweight | Maintain | Jul 16, 2026 |
Named analyst price targets
Upside is calculated against the persisted current price $12.15. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| UBS | Analyst unavailable | $17.5 | $13.82 | +44.0% | Aug 24, 2026 |
| Stephens | Poorah Sharma | $17 | $13.65 | +39.9% | Aug 17, 2026 |
| Barclays | Analyst unavailable | $20 | $12.1 | +64.6% | Jul 16, 2026 |
| UBS | Analyst unavailable | $17 | $12.52 | +39.9% | May 19, 2026 |
| Barclays | Analyst unavailable | $23 | $17.03 | +89.3% | Mar 27, 2026 |
| UBS | Analyst unavailable | $19.5 | $15.73 | +60.5% | Feb 5, 2026 |
| Banco Santander | Guilherme Palhares | $17 | $14.03 | +39.9% | Dec 11, 2025 |
| Goldman Sachs | Analyst unavailable | $18.5 | $14.53 | +52.3% | Nov 26, 2025 |
| Mizuho Securities | Analyst unavailable | $20 | $13.16 | +64.6% | Oct 28, 2025 |
Track every rating change on JBS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationJBS NV is a food company that engages in the sale of beef, pork, lamb meat and poultry products. It offers its products to supermarkets, club stores, other retail distributors, and foodservice companies. The company was founded on October 9, 2019 and is headquartered in Amstelveen, the Netherlands.
Historical context
All JBS earningsLatest beats and misses
Who reports nextBeat on EPS
- VGFY2026 Q3 · November 10, 2026+92.7% EPS+1.7% move
- TDGFY2026 Q4 · November 10, 2026+1.9% EPS+0.5% move
- ONONFY2026 Q3 · November 10, 2026+39.9% EPS-7.5% move
- CRWVFY2026 Q3 · November 10, 20260.0% EPS-0.5% move
- OXYFY2026 Q3 · November 9, 2026+30.8% EPS+2.0% move
- MGREFY2026 Q3 · November 9, 2026+8.1% EPS+0.6% move
Missed on EPS
- EMBJFY2026 Q3 · November 10, 2026-49.4% EPS+7.0% move
- VODFY2027 Q2 · November 10, 2026-72.8% EPS-1.2% move
- SEFY2026 Q3 · November 10, 2026-5.1% EPS-1.5% move
- BAPFY2026 Q3 · November 9, 2026-2.6% EPS+3.3% move
- CIBFY2026 Q3 · November 9, 2026-10.1% EPS-4.0% move
- ASTSFY2026 Q3 · November 9, 2026-8.9% EPS-2.3% move
Get the JBS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-10T22:12:56.186529+00:00
- FN2 earnings calendar · 2026-11-10T01:23:14.443147+00:00
- Polygon adjusted daily market bars · 2026-11-10T22:30:47.274549+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-10T22:30:47.271819+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-10. For educational purposes only; not investment advice.